Jessica J Lin Selected Research

pralsetinib

1/2022	Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
1/2021	An early look at selective RET inhibitor resistance: new challenges and opportunities.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jessica J Lin Research Topics

Disease

23	Neoplasms (Cancer) 05/2022 - 06/2015
20	Lung Neoplasms (Lung Cancer) 10/2022 - 01/2016
14	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 04/2016
7	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2016
4	Brain Neoplasms (Brain Tumor) 01/2019 - 01/2017
3	Disease Progression 01/2022 - 01/2020
1	Edema (Dropsy) 07/2022
1	Thyroid Neoplasms (Thyroid Cancer) 04/2022
1	Chylous Ascites 01/2022
1	Chylothorax 01/2022
1	Pneumonia (Pneumonitis) 01/2021
1	COVID-19 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021
1	Urinary Bladder Neoplasms (Bladder Cancer) 10/2020
1	Melanoma (Melanoma, Malignant) 10/2020
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020
1	medullary Thyroid cancer 01/2020
1	Adenocarcinoma of Lung 04/2016
1	Breast Neoplasms (Breast Cancer) 06/2015

Drug/Important Bio-Agent (IBA)

9	Tyrosine Kinase InhibitorsIBA 10/2022 - 04/2016
8	lorlatinibIBA 10/2022 - 01/2018
6	CrizotinibIBA 07/2022 - 01/2017
5	Anaplastic Lymphoma KinaseIBA 01/2022 - 01/2017
4	entrectinibIBA 05/2022 - 01/2021
4	Immune Checkpoint InhibitorsIBA 11/2021 - 01/2018
3	selpercatinibIBA 01/2022 - 01/2020
3	Phosphotransferases (Kinase)IBA 01/2022 - 01/2022
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 10/2018
3	Circulating Tumor DNAIBA 01/2020 - 01/2018
3	alectinibIBA 11/2019 - 11/2016
2	larotrectinibIBA 04/2022 - 01/2022
2	TropomyosinIBA 01/2022 - 01/2022
2	pralsetinibIBA 01/2022 - 01/2021
2	osimertinibIBA 01/2022 - 01/2019
2	cabozantinibIBA 01/2021 - 10/2018
2	SolventsIBA 01/2020 - 10/2018
2	ErbB Receptors (EGF Receptor)IBA 01/2020 - 04/2016
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019 - 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Triglycerides (Triacylglycerol)IBA 01/2022
1	LigandsIBA 11/2021
1	pembrolizumabIBA 11/2021
1	B7-H1 AntigenIBA 07/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	adagrasibIBA 01/2021
1	sotorasibIBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	capmatinibIBA 01/2021
1	VaccinesIBA 10/2020
1	Cell-Free Nucleic AcidsIBA 01/2019
1	Biological ProductsIBA 12/2018
1	repotrectinibIBA 10/2018
1	Sunitinib (Sutent)FDA Link 10/2018
1	vandetanib (ZD6474)IBA 10/2018
1	Gefitinib (Iressa)FDA Link 04/2016
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2016
1	Phenobarbital (Luminal)FDA Link 06/2015

Therapy/Procedure

18	Therapeutics 04/2022 - 01/2016
3	Drug Therapy (Chemotherapy) 11/2021 - 04/2016
2	Immunotherapy 01/2018 - 01/2017
1	Drug Tapering 07/2022
1	Aftercare (After-Treatment) 01/2020
1	Radiotherapy 01/2018